Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gefitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 18/20 | 1.00 |
| ▸ | KDR | P35968 | 3/20 | 1.00 |
| ▸ | BRAF | P15056 | 2/20 | 1.00 |
| ▸ | EPHB4 | P54760 | 2/20 | 1.00 |
| ▸ | FLT4 | P35916 | 2/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 1.00 |
| ▸ | STK17B | O94768 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | CHEK2 | O96017 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gefitinib SCHEMBL465143 | 1.00 | EGFR (1.00) | EGFRKDRBRAFEPHB4FLT4 | |
| SCHEMBL1734701 | 1.00 | EGFR (1.00) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL29351336 | 1.00 | EGFR (1.00) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL29351046 | 1.00 | EGFR (1.00) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL28098790 | 0.99 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL29371159 | 0.99 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL2770155 | 0.99 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL28097850 | 0.99 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL11776 | 0.99 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL30887946 | 0.99 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 127784 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747285-A1 | MONOCLONAL ANTIBODIES AGAINST PCDH7 FOR LUNG CANCER THERAPY | The Board of Regents of the University of Texas System (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4746970-A1 | EGFR ANTAGONISTS FOR THE TREATMENT OF DISEASES INVOLVING UNWANTED MIGRATION, PROLIFERATION, AND/OR METAPLASIA OF RETINAL PIGMENT EPITHELIUM (RPE) CELLS | Jonas, Jost B. (DE) | 2026-05-27 | — | — | EP | claimed |
| CN-122075497-A | Use of NLRP3 agonist for tumor treatment | — | 2026-05-26 | — | — | CN | claimed |
| CN-122075716-A | Medicine for treating tumor by combining recombinant oncolytic virus and small-molecule anticancer medicine | — | 2026-05-26 | — | — | CN | claimed |
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| CN-122074043-A | Combination therapy with KRAS modulators | 光达治疗公司 | 2026-05-22 | — | — | CN | claimed |
| US-20260137685-A1 | SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2026-05-21 | — | — | US | claimed |
| US-20260137686-A1 | SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2026-05-21 | — | — | US | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| WO-2026103823-A1 | COMBINATION OF RAS INHIBITOR AND EGFR INHIBITOR AND USE THEREOF | 广州嘉越医药科技有限公司 | 2026-05-21 | — | — | WO | claimed |
| WO-2002056692-A1 | METHODS FOR MODULATING TUMOR GROWTH AND METASTASIS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-07-25 | — | — | WO | claimed |
| EP-1225233-A2 | Means and methods for treatment evaluation | Amsterdam Support Diagnostics B.V. (NL) | 2002-07-24 | — | — | EP | claimed |
| WO-2002045717-A1 | LOMETREXOL COMBINATION THERAPY | TULARIK INC. (US) | 2002-06-13 | — | — | WO | claimed |
| US-20020061304-A1 | Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor | PFIZER PRODUCTS INC. & OSI PHARMACEUTICALS, INC. | 2002-05-23 | — | — | US | claimed |
| WO-2002018368-A1 | TRICYCLIC ANTITUMOR COMPOUNDS BEING FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2002-03-07 | — | — | WO | claimed |
| US-20020002162-A1 | Synergistic methods and compositions for treating cancer | BRISTOL-MYERS SQUIBB COMPANY | 2002-01-03 | — | — | US | claimed |
| WO-2001072721-A2 | SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-10-04 | — | — | WO | claimed |
| WO-2001070255-A2 | COMBINED TREATMENT WITH KERATINOCYTE GROWTH FACTOR AND EPIDERMAL GROWTH FACTOR INHIBITOR | PFIZER PRODUCTS, INC. (US) | 2001-09-27 | — | — | WO | claimed |
| EP-0823900-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-12-27 | — | — | EP | claimed |
| US-5770599-A | RECEPTOR TYROSINE KINASE INHIBITORS including 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(2-morpholinoethoxy)quinazoline (gefitinib) | ZENECA LIMITED (GB) | 1998-06-23 | — | — | US | claimed |